PurpleLab® and Comscore Partner to Deliver 'Off-the-Shelf' Healthcare Predictive Audiences in The Trade Desk
WAYNE, Pa.--(BUSINESS WIRE)-- PurpleLab®, a leading provider of real-world healthcare claims data in the US, and Comscore, a global leader in measuring and analyzing consumer behavior, today announced a strategic partnership to make PurpleLab's robust healthcare targeting segments available as ID-free Predictive Audiences directly on The Trade Desk's Contextual Marketplace.
The partnership addresses the changes to state privacy regulations impacting the pharma advertising industry and provides an ID-free targeting solution to effectively target healthcare audiences. By combining PurpleLab's extensive 330+ million de-identified claims data with Proximic by Comscore's powerful AI contextual intelligence, the new ID-free Predictive Audiences offer advertisers a privacy-minded, scalable, and more precise way to reach their ideal healthcare consumers.
"We are excited to partner with Comscore to bring our rich healthcare audiences to The Trade Desk in such an accessible way," said Scott Ronay, VP, Sales, Advertising Solutions at PurpleLab. "This collaboration allows advertisers to contextually target valuable health audiences, all while enabling a high level of privacy features. The 'off-the-shelf' availability on the Trade Desk's Contextual Marketplace significantly streamlines the activation process, allowing our clients to easily reach their preferred contextual healthcare audience across desktop, mobile, CTV, and audio."
Through this collaboration, PurpleLab health data is translated into privacy-by-design, ID-free audience segments that can be targeted programmatically across all 50 states. This assists brands to more confidently reach health-focused consumers at scale, without compromising compliance or coverage.
'Advertisers need innovative solutions that deliver both reach and accuracy without relying on personal identifiers. Our partnership with PurpleLab is a testament to our commitment to providing future-proof targeting capabilities,' said Rachel Gantz, Managing Director of Proximic by Comscore. "By leveraging Comscore's currency-grade data and AI, we are extending the reach of PurpleLab's valuable ID-based audiences, offering advertisers increased scale and preserving the targeting accuracy they've come to expect."
The new PurpleLab x Comscore Predictive Audiences are now available 'off-the-shelf' in The Trade Desk's Contextual Marketplace.
About PurpleLab®:
PurpleLab® is a healthcare analytics company dedicated to driving value-driven innovation across the healthcare continuum. Its no-code analytics platform, HealthNexus™, empowers life sciences, payers, providers, advertisers, and other healthcare stakeholders to develop real-world evidence (RWE), demonstrating the effectiveness of novel therapeutics or clinical strategies in saving lives and reducing costs.
As one of the few CMS Qualified Entities, PurpleLab has access to Medicare claims data under Parts A, B, and D, enabling the evaluation of provider performance. The company is also a member of the Network Advertising Initiative (NAI), adhering to the highest standards for responsible data collection and usage in digital advertising. Additionally, PurpleLab holds HiTRUST certification, meeting the rigorous security and privacy requirements essential in healthcare data management.
For more information, visit purplelab.com.
About Comscore
Comscore is a global, trusted partner for planning, transacting and evaluating media across platforms. With a data footprint that combines digital, linear TV, over-the-top and theatrical viewership intelligence with advanced audience insights, Comscore empowers media buyers and sellers to quantify their multiscreen behavior and make meaningful business decisions with confidence. A proven leader in measuring digital and TV audiences and advertising at scale, Comscore is the industry's emerging third-party source for reliable and comprehensive cross-platform measurement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Securonix Acquires ThreatQuotient to Deliver Industry's Broadest and Deepest Threat Detection Investigation and Response
PLANO, Texas--(BUSINESS WIRE)--Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of ThreatQuotient, a four-time leader in threat intelligence based on QKS Group Spark Matrix report and the force behind ThreatQ, the most innovative external threat intelligence platform. This combination will create a comprehensive, modular, and fully integrated AI-driven platform for threat detection, investigation, and response (TDIR), leveraging advanced analytics and insights across both internal and external threats. This acquisition accelerates the modernization of security operations by uniting internal and external threat intelligence with real-time analytics and agentic AI. Unlike external threat intelligence bolt-on solutions with disconnected management interfaces, the integrated platform from Securonix and ThreatQuotient will deliver unified visibility, faster response, and greater operational clarity. "Bringing threat intelligence management and SIEM together in a unified platform is a game changer. We've already seen the value of deeply enriched advanced analytics and detection in our Securonix SIEM environment—but coupling that with integrated threat curation, prioritization, and response should help customers move even faster. It means fewer swivel-chair investigations, more accurate triage, and greater confidence that security analysts are working with the most relevant threats. This kind of integration has the potential to accelerate the ability to detect, respond, and stay ahead," said Marcel Jonker, Director of Cybersecurity Operations at Cambia Health Systems. The integration of Securonix and ThreatQuotient promises to deliver up to a 70% reduction in Mean Time to Respond (MTTR), enabling security teams to detect, investigate, and remediate threats significantly faster. By combining curated threat intelligence with AI-driven automation, the solution will deliver exponential improvements in filtering out false positives, enriching alerts with actionable context, and automating historical threat sweeps and incident response. This reduces alert overload, speeds up root cause analysis, and minimizes manual handoffs—cutting investigation time from hours to minutes and enabling automated containment before threats escalate. 'Security teams are drowning in noise and struggling to keep up with evolving threats,' said Kash Shaikh, CEO and President of Securonix. 'This acquisition brings together Securonix's Agentic AI-driven Platform with ThreatQuotient's deep threat intelligence to deliver clarity, speed, and automated workflows to our customers, reducing false positives by up to 90%. Together, we're building the modern SOC Platform—proactive, intelligent, and built for what's next.' Kash added, 'Securonix and ThreatQuotient bring together complementary strengths—deep innovation across internal and external threat domains, and a shared commitment to innovation and customer service. Both companies serve enterprise and government customers as well as managed security service providers (MSSPs), and we're excited to welcome the talented ThreatQuotient team and their customers to Securonix.' Purpose-Built for Analysts. Proven Against Real-World Threats. ThreatQuotient's Threat Intelligence Platform (TIP) strength lies in delivering curated, contextualized threat intelligence that drives smart, timely decisions. When combined with Securonix's EON Agentic AI-based SIEM, SOAR, UEBA and Data Pipeline Manager, customers can accelerate their migration from reactive threat hunting-based defense to proactive, real-time, behavior-driven, open-agentic security operations. With this integration, Securonix customers and partners will enjoy the following benefits: Gain clear visibility: Integrate deep enriched real-time analytics from Securonix with curated external intelligence from ThreatQuotient to create a single, high-context stream of alerts. Eliminate blind spots and accelerate threat identification with confidence. Stay ahead of risk: Auto-enrich Indicator of compromise (IoCs) and preemptively respond to repeat attacks, blocking 90 percent before they start. Act smarter: Automate repetitive tasks, reduce false positives, and streamline investigations. Teams can stay focused on high-priority threats and reduce time spent on manual triage. Deploy your way: Continue to use ThreatQ as a standalone threat intelligence platform or as part of the fully integrated Securonix solution. Deploy on-premise or SaaS in a way that fits the current architecture and scales with needs. Accelerated Roadmap: Combined R&D synergies will accelerate upcoming roadmap innovations, including Agentic AI and ThreatQuotient's innovation priorities. With this acquisition, ThreatQuotient customers and partners will enjoy the following benefits: Increased Scale: ThreatQ customers can take advantage of Securonix's global R&D scale and GTM reach, including access to Securonix's Threat Labs Intelligence. Deeper Integrations: Gain access to an enriched roadmap and integration between Securonix's best-in-class SIEM, SOAR, and UEBA portfolio and ThreatQ, including extension of Agentic AI advancements. Continued Focus: Zero interruption of their existing service, as ThreatQuotient will continue to operate as a standalone offering, with no disruption to existing roadmap and workflows. 'Enterprises, government institutions and managed security service providers rely on ThreatQuotient to protect their mission critical businesses. Joining Securonix marks a powerful new chapter for ThreatQuotient. By uniting our strengths, we can accelerate innovation, expand our reach, and deliver greater value to our customers. I'm proud of what we've built and excited for what's ahead,' said John Czupak, CEO of ThreatQuotient. BTIG, LLC served as exclusive financial advisor, and King & Spalding LLP served as legal advisor to ThreatQuotient. Vinson & Elkins LLP served as legal advisor to Securonix. About Securonix Securonix is leading the transformation of cybersecurity with the industry's first Unified Defense SIEM powered by agentic AI, purpose-built to decide and act across the threat lifecycle with a human-in-the-loop philosophy. Built for scale, precision, and speed, our cloud-native platform empowers global enterprises to shift from reactive security to proactive, autonomous operations. Recognized as a Leader in the Gartner® Magic Quadrant™ for SIEM and a Customers' Choice by Gartner Peer Insights™, Securonix is driving the next era of intelligent, autonomous security operations. Learn more at About ThreatQuotient ThreatQuotient improves security operations by fusing disparate data sources, tools, and teams to accelerate threat detection, investigation, and response (TDIR). ThreatQ is the first purpose-built, data-driven threat intelligence platform that helps teams prioritize, automate, and collaborate on security incidents; enables more focused decision-making; and maximizes limited resources by integrating existing processes and technologies into a unified workspace. The result is reduced noise, clear priority threats, and the ability to automate processes with high-fidelity data. ThreatQuotient's leading integration marketplace, data management, orchestration, and automation capabilities support multiple use cases including threat intelligence management and sharing, incident response, threat hunting, spear phishing, alert triage, and vulnerability management. For more information, visit
Yahoo
4 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Tenet Provides Update on Delayed Filing of Year-End 2024 Financial Results
Toronto, Ontario--(Newsfile Corp. - June 13, 2025) - Tenet Fintech Group Inc. (CSE: PKK) (OTCQB: PKKFF) ("Tenet" or the "Company"), an innovative analytics service provider, owner and operator of the Cubeler® Business Hub, today announced that completing the audit of the Company's year-end 2024 financial statements (the "Financial Statements") would take longer than originally expected, in part due to the transition of the Company's operations in China and the impact on the Company's revenue, and the late start to the audit process affecting the availability of resources. The Company has now set the week of July 14, 2025 as the revised target date to complete the audit and filing of the Financial Statements following a recent meeting with the Company's auditors during which the matter was discussed. Upcoming Cubeler Business Hub Improvements Tenet would like to take this opportunity to thank all Cubeler Business Hub users who have provided, and continue to provide, feedback on their experiences with the platform. The information has been extremely valuable to the Company and has led to several improvements, particularly to the Networking and Insights modules, to be reflected in a relaunch of the platform this summer before its expansion to the United States. Tenet Chief Operating Officer, Mayco Quiroz, will be previewing some of the platform's new and improved features in a short recorded video to be released on June 20, 2025. About Tenet Fintech Group Inc.: Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial intelligence (AI) companies. All references to Tenet in this news release, unless explicitly specified, include Tenet and all its subsidiaries. Tenet's subsidiaries offer various analytics and AI-based products and services to businesses, capital markets professionals, government agencies and financial institutions either through or leveraging data gathered by the Cubeler® Business Hub, a global ecosystem where analytics and AI are used to create opportunities and facilitate B2B transactions among its members. Please visit our website at: For more information, please contact: Tenet Fintech Group Quiroz, Chief Operating Officer514-340-7775 ext.: 510investors@ CHF Capital MarketsCathy Hume, CEO416-868-1079 ext.: 251cathy@ Follow Tenet Fintech Group Inc. on social media: X: @Tenet_Fintech Facebook: @Tenet LinkedIn: Tenet YouTube: Tenet Fintech Forward-Looking Information Certain statements in this press release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors which may cause actual results, performance or achievements of Tenet to be materially different from the outlook or any future results, performance or achievements implied by such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements. Important risk factors that could affect the forward-looking statements in this news release include, but are not limited to, holding company with significant operations in China; general economic and business conditions, including factors impacting the Company's business in China such as pandemics and COVID-19; legislative and/or regulatory developments; Global Financial conditions, repatriation of profits or transfer of funds from China to Canada, operations in foreign jurisdictions and possible exposure to corruption, bribery or civil unrest; actions by regulators; uncertainties of investigations, proceedings or other types of claims and litigation; timing and completion of capital programs; liquidity and capital resources, negative operating cash flow and additional funding, dilution from further financing; financial performance and timing of capital; and other risks detailed from time to time in reports filed by Tenet with securities regulators in Canada. Reference should also be made to Management's Discussion and Analysis (MD&A) in Tenet's annual and interim reports, Annual Information Form, filed with Canadian securities regulators and available via the System for Electronic Document Analysis and Retrieval (SEDAR+) under Tenet's profile at for a description of major risk factors relating to Tenet. Although Tenet has attempted to identify certain factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements reflect information as of the date on which they are made. The Company assumes no obligation to update or revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, unless required by applicable securities laws. In the event the Company does update any forward-looking statement, no inference should be made that the Company will make additional updates with respect to that statement, related matters, or any other forward-looking statement. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
